FTO and ovarian carcinoma: The downregulation of FTO and ALKBH5 in ovarian cancers with breast-cancer susceptibility gene 2 (BRCA2) mutations enhanced FZD10 mRNA m6A modifications, which ultimately reduced the sensitivity of PARPi via the Wnt/β-catenin pathway [138].